Skip to main content

Table 1 Age-specific varicella-zoster virus seroprevalence (%, 95 % CI) among a subset of Norwegian population (n = 2,103)

From: Varicella-zoster virus susceptibility and primary healthcare consultations in Norway

Age group Positive   Negative   Equivocal  
% (No of samples) 95 % CI % (No of samples) 95 % CI % (No of samples) 95 % CI
0 y 58.9 (56) 48.8–68.4 29.5 (28) 21.1–39.4 11.6 (11) 6.5–19.8
1 y 11.2 (12) 6.5–18.8 86.9 (93) 79.1–92.1 1.9 (2) 0.5–7.2
2 y 16.3 (17) 10.4–24.8 77.9 (81) 68.9–84.9 5.8 (6) 2.6–12.3
3 y 40.2 (41) 31.1–50.0 55.9 (57) 46.1–65.2 3.9 (4) 1.5–10.0
4 y 48.5 (49) 38.9–58.2 50.5 (51) 40.8–60.2 1.0 (1) 0.1–6.8
5 y 65.3 (66) 55.5–74.0 33.7 (34) 25.1–43.5 1.0 (1) 0.1–6.8
6 y 69.8 (67) 59.8–78.2 26.0 (25) 18.2–35.8 4.2 (4) 1.6–10.6
7 y 71.4 (70) 61.7–79.5 24.5 (24) 17.0–34.0 4.1 (4) 1.5–10.4
8 y 82.8 (82) 74.0–89.1 15.2 (15) 9.3–23.7 2.0 (2) 0.5–7.8
9 y 78.1 (75) 68.7–85.3 16.7 (16) 10.4–25.5 5.2 (5) 2.2–12.0
10–14 y 81.4 (118) 74.2–86.9 11.7 (17) 7.4–18.1 6.9 (10) 3.7–12.4
15–19 y 89.5 (94) 82.0–94.1 4.8 (5) 2.0–11.0 5.7 (6) 2.6–12.2
20–24 y 86.4 (89) 78.3–91.8 8.7 (9) 4.6–16.0 4.9 (5) 2.0–11.2
25–29 y 90.0 (81) 81.8–94.7 10.0 (9) 5.3–18.2 0 (0) -
30–34 y 91.9 (79) 83.8–96.1 2.3 (2) 0.6–8.9 5.8 (5) 2.4–13.3
35–39 y 95.7 (90) 89.1–98.4 1.1 (1) 0.1–7.2 3.2 (3) 1.0–9.5
40–44 y 91.8 (89) 84.3–95.8 1.0 (1) 0.1–7.0 7.2 (7) 3.5–14.4
45–49 y 94.8 (91) 88.0–97.8 3.1 (3) 1.0–9.3 2.1 (2) 0.5–8.0
50–59 y 95.9 (94) 89.6–98.5 3.1 (3) 1.0–9.1 1.0 (1) 0.1–7.0
60–69 y 95.8 (91) 89.3–98.4 3.2 (3) 1.0–9.4 1.1 (1) 0.1–7.2
70+ y 93.7 (89) 86.6–97.1 1.1 (1) 0.1–7.2 5.3 (5) 2.2–12.1
Total 73.2 (1540) 71.3–75.1 22.7 (478) 21.0–24.6 4.0 (85) 3.3–5.0